Navigation Links
Research Indicates Geron's Human Embryonic Stem Cell-Based,Therapeutic for Spinal Cord Injury Evades Direct Attack by the,Human Immune System

MENLO PARK, Calif.--(BUSINESS WIRE)--Jun 11, 2007 - Geron Corporation (Nasdaq:GERN) today announced the presentation of research studies indicating that GRNOPC1, the company's human embryonic stem cell (hESC)-based therapeutic for the treatment of spinal cord injury, evades a direct attack by the human immune system.

Presented by Geron scientist Ross Okamura at the Federation of Clinical Immunology Societies meeting in San Diego, the findings could mean that patients treated with GRNOPC1 would require significantly lower doses and/or shorter courses of immunosuppression than what are required for patients who undergo solid organ transplants.

"The results imply that our cell-based therapeutic, unlike traditional solid organ transplants, is minimally recognized by the human immune system," said Thomas B. Okarma, Ph.D, M.D., Geron's president and chief executive officer. "Because GRNOPC1 cells are allogenic, it was expected that they would be recognized and destroyed by multiple immune rejection modulators. This isn't the case. The benefit to patients is that a reduction in the requirement for immunosuppression decreases the potential for untoward side effects that are common with those types of drugs."

The data indicate that GRNOPC1 cells have low susceptibility to both direct cell and antibody-mediated immune responses. The data also show that GRNOPC1 cells do not widely express non-human antigens, such as Neu5GC, that might have originated from mouse feeder cells to which the original hESC cell line was exposed in its initial derivation. Expression of such non-human antigens would typically lead to lysis by antibodies present in the sera of normal individuals.

In the studies, GRNOPC1 cells were tested for susceptibility to both immune effector cells and sera from normal healthy individuals. GRNOPC1 cells stimulated very low levels of T cell proliferation. Allogenic T cell proliferation is a standard measure of immune recognition of foreign transplanted tissue. Even when GRNOPC1 cells were exposed to proinflammatory cytokines, such as gamma interferon or TNF alpha, allogeneic T cell proliferation was not induced.

In addition, GRNOPC1 cells were not lysed by natural killer cells, the "innate" arm of the immune system. Finally, GRNOPC1 cells were largely resistant to killing by antibodies present in the sera of normal healthy individuals. Sera from eight of 10 individuals failed to induce the killing of GRNOPC1 cells. The sera from the remaining two individuals induced only 10% GRNOPC1 cell lysis.

GRNOPC1 is an allogeneic population of cells containing oligodendroglial progenitors that is intended for transplantation into the lesion site of patients with spinal cord injury to induce tissue repair. Geron's development plan for the product calls for the filing of an Investigational New Drug (IND) Application with the U.S. Food and Drug Administration later this year pending the outcome of ongoing safety studies.

Geron is developing first-in-class biopharmaceuticals for the treatment of cancer and chronic degenerative diseases, including spinal cord injury, heart failure, diabetes and HIV/AIDS. The company is advancing an anti-cancer drug and a cancer vaccine that target the enzyme telomerase through multiple clinical trials. Geron is also the world leader in the development of human embryonic stem cell-based therapeutics, with its spinal cord injury treatment anticipated to be the first product to enter clinical development. For more information, visit www.geron.com.

This news release may contain forward-looking statements made pursuant to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Investors are cautioned that such forward-looking statements in this press release regarding potential applications of Geron's human embryonic stem cell technology constitute forward-looking statements that i nvolve risks and uncertainties, including, without limitation, risks inherent in the development and commercialization of potential products, uncertainty of clinical trial results or regulatory approvals or clearances, need for future capital, dependence upon collaborators and maintenance of our intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements. Additional information on potential factors that could affect our results and other risks and uncertainties are detailed from time to time in Geron's periodic reports, including the quarterly report on Form 10-Q for the quarter ended March 31, 2007.

Contact

Geron
David L. Greenwood, 650-473-7765
Chief Financial Officer
info@geron.com
or
Russo Partners, LLC
David Schull, 858-717-2310 (Media)
david.schull@russopartnersllc.com
Matthew Haines, 212-845-4235 (Investors)
matthew.haines@russopartnersllc.com


'"/>




Related medicine technology :

1. NIEHS Researchers Identify Enzyme Critical in DNA Replication
2. Stanford Researchers Find Brain Pathway of Depression in Rats
3. Suven Life Sciences Presenting Pre-clinical data of their NCE’s SUVN-502 and SUVN-507at International Brain Research Organization (IBRO) 2007 World Congress of Neuroscience
4. From Clinical Cancer Research: Rethinking Therapeutic Cancer Vaccine Trials
5. Researchers Discover Method for Identifying How Cancer Evades the Immune System
6. Infertile Voice Supports Stem Cell Research: RESOLVE Calls for Patient Options in Using Frozen Embryos
7. Fact Sheet: Advancing Stem Cell Research While Respecting Moral Boundaries
8. President Bush Ignores Americas Plea for Support of Stem Cell Research
9. Researchers Discover Gene For Rare Skin Disorder
10. The Christopher and Dana Reeve Foundation Expresses Disappointment Over President Bushs Veto of the Stem Cell Research Enhancement Act
11. Research on New Treatment for Neglected Disease Published in The New England Journal of Medicine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/27/2016)... 2016 According to the 2016 ... driving ambulatory blood pressure monitoring system market growth. With ... ability to respond to different pressure rates, leading to ... to various cardiovascular disorders such as heart failure, stroke, ... are growing in prevalence each year. WHO estimates that ...
(Date:5/26/2016)... May 26, 2016 According to a ... Management Market - U.S. Industry Analysis, Size, Share, Growth, Trends, ... in the U.S. was valued at US$ 5.89 Bn in ... 3.4% from 2015 to 2023 to reach US$ 7.99 Bn ... current and emerging needle free drug delivery devices and the ...
(Date:5/25/2016)... May 25,2016 FDA 510(k) ... Cellvizio platform for urological and surgical applications ... inventor of Cellvizio®, the multidisciplinary confocal laser endomicroscopy ... in the US with the 12 th ... Administration (FDA). This new FDA clearance covers Confocal ...
Breaking Medicine Technology:
(Date:5/31/2016)... (PRWEB) , ... May 31, 2016 , ... In a ... Paul Feiner and broadcast on New Rochelle, NY-based WVOX (1460 AM), leading ... create what she calls the country’s “modern medical money maelstrom.” , During the ...
(Date:5/31/2016)... ... May 31, 2016 , ... Advertising Age has recognized ... provider, for the tenth consecutive year as a Top 20 Marketing Services Agency. ... SourceLink ranked eighteenth in the “U.S. CRM/Direct Marketing Agency” category. , Recent ...
(Date:5/31/2016)... Port Washington, NY (PRWEB) , ... May 31, 2016 , ... ... and other essential nutrients to on the go individuals and dedicated athletes, continues to ... functions. , Loaded with whey, pea and milk protein, branched-chain amino acids (BCAA), ...
(Date:5/30/2016)... (PRWEB) , ... May 30, 2016 , ... ... small businesses, announced today the publication of an original infographic, " Health Benefits ... health insurance professionals understand how Zane Benefits complies with various federal regulations and ...
(Date:5/29/2016)... ... May 29, 2016 , ... Whole Health Supply is happy ... that has been available via Amazon.com. This new style of nail clipper has a ... jaw opening is approximately 4mm and the actual handle is 2.5mm thick to accommodate ...
Breaking Medicine News(10 mins):